Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893827 · ClinicalTrials.gov registry record · Phase 4
Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 237
- Enrollment target
NCT01893827 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 237 participants.
The verdict
NCT01893827, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 237 participants
- Enrollment target
Study Summary
The proposed study is a pragmatic, randomized, open-label clinical trial of 24 weeks of XR-NTX vs. O-NTX using a COMBINE-adapted Medical Management primary care treatment model. 237 adults \>18yo with alcohol dependence will be recruited from the community into treatment in public sector primary care settings. The primary outcome which powers this study is a dichotomous good clinical outcome defined by abstinence or moderate drinking, and as measured by the Timeline Follow-back and analyzed using an intention-to-treat approach among all randomized participants. Secondary outcomes include the incremental cost effectiveness of the two arms, differences between arms by continuous measures of alcohol intake (drinks/day, % days abstinent, time to first heavy drinking day, bio-markers), and the exploratory analysis of factors possibly associated with effectiveness, including gender, prior treatment abstinence, and mu opioid receptor (OPRM1) genotypes. Specific Aim 1: Treatment Effectiveness. To evaluate the effectiveness of extended-release naltrexone (XR-NTX) vs. oral naltrexone (O-NTX) in producing a primary good clinical outcome, defined as abstinence or moderate drinking (≤2 drinks/day, men; ≤1 drink/day,women; and ≤2 heavy drinking occasions/month), during the final 20 of 24 weeks of primary care-based Medical Management for alcohol dependence. Hypothesis: The rate of this good clinical outcome will be approximately twice as great among participants receiving XR-NTX compared with those receiving O-NTX. Specific Aim 2: Cost Effectiveness. To estimate the incremental cost effectiveness of XR-NTX vs. O-NTX,both in conjunction with primary care-based Medical Management. Hypothesis: XR-NTX treatment will be more cost effective than O-NTX. Specific Aim 3: Patient-Level Predictors of Effectiveness. To identify patient-level characteristics associated with effectiveness in both arms.
Interventions
- DRUG XR-NTX (Extended-Release Naltrexone)
- DRUG Oral Naltrexone (O-NTX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01893827
The ClinicalTrials.gov registry entry for NCT01893827 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XR-NTX (Extended-Release Naltrexone) is the first listed.
NCT01893827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01893827 about?
NCT01893827 is a clinical study titled "Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care". The proposed study is a pragmatic, randomized, open-label clinical trial of 24 weeks of XR-NTX vs. O-NTX using a COMBINE-adapted Medical Management primary care treatment model. 237 adults \>18yo with alcohol dependence will be recruited from the community into treatment in public sector primary car...
What is the current status of trial NCT01893827?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 237 participants. The study started on 2014-06. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT01893827?
The interventions under investigation include: XR-NTX (Extended-Release Naltrexone) (DRUG), Oral Naltrexone (O-NTX) (DRUG).
Who is sponsoring clinical trial NCT01893827?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.